Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
作者:
主题词
骨密度保护剂(Bone Density Conservation Agents);骨肿瘤(Bone Neoplasms);费用效益分析(Cost-Benefit Analysis);卫生经费支出(Health Expenditures);人类(Humans);Markov链(Markov Chains);模型, 经济学(Models, Economic);肿瘤转移(Neoplasm Metastasis);处方费(Prescription Fees);质量校正寿命(Quality-Adjusted Life Years);美国(United States)
DOI
10.1080/13696998.2019.1651122
PMID
31364885
发布时间
2020-06-30
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文